Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Sat Kartar Shopping Ltd.

SATKARTAR

Equity

NSE

Min. Investment

77,000.00

Open a free Demat account and invest in IPOs easily.

Download Orca

Google PlayApp Store

To access realtime data for GP Eco Solutions India Ltd. and use advance features for Applying IPO. Register or Login to Orca.

IPO Details

Bidding Dates

10 Jan 25 - 14 Jan 25

Price Range ₹

77 - 81

Total Equity

33.80Cr

Lot Size

1600

Exchange Status

NSE

IPO Doc

Subscription Rate

Non-Institutional Investor

0.00×

Qualified Institutional Buyers

0.00×

Employees

0.00×

Retail Investors

0.00×

Total subscription Rate

0.00×

IPO Timeline

Offer start

10 Jan 2025

Offer end

14 Jan 2025

Allotment

15 Jan 2025

Refund initiation

16 Jan 2025

Demat transfer

16 Jan 2025

Listing

17 Jan 2025

About Company

Sat Kartar Shopping Limited is committed to delivering holistic wellness solutions rooted in the principles of Ayurveda, offering a diverse range of products tailored to the specific health needs of its consumers. The company's product portfolio is thoughtfully divided into two primary categories: niche therapeutic solutions and lifestyle-driven remedies. In the niche therapeutic category, the company addresses specific health challenges that require targeted solutions. These products are designed to help individuals combat issues such as addiction, personal care, and general wellness. Flagship products in this segment include *Addiction Killer* and *Liv Muztang,* which are tailored to meet the needs of consumers seeking effective remedies for these specific problems. In addition to therapeutic solutions, the company focuses on lifestyle-driven healthcare products aimed at addressing health issues stemming from modern living. This category includes remedies for conditions such as diabetes, joint pain, piles, and other lifestyle-related concerns. Recognizing the evolving needs of its consumers, Sat Kartar Shopping Limited is actively diversifying its product offerings to include solutions for weight management, hair care, gut health, PCOD (Polycystic Ovary Disease), and mental wellness. By addressing these areas, the company strives to provide a comprehensive approach to health and well-being, ensuring that its products cater to a wide range of consumer requirements. The company’s operations are supported by a robust workforce of 1,122 employees as of November 30, 2024, working across various departments. This dedicated team plays a vital role in ensuring the seamless delivery of high-quality products and services to consumers nationwide. Sat Kartar Shopping Limited’s commitment to innovation, coupled with its strong focus on traditional Ayurveda practices, positions it as a key player in the natural healthcare sector.

Year Founded

29-06-2012

Promotor Details

Promoter Holdings Details

ParticularPre-IPOPost-IPO
Percentage85.8963.13
Share Capital99397529968356

Offer to Public

41,72,800.00 Cr

Project Details

  • Unidentified Acquisition (In India & Abroad) - 50cr
  • Capital Expenditures - 80cr
  • Investment in Technology - 50cr
  • Marketing and Advertisement - 110cr

Objectives

  • To meet out the expenses of Unidentified Acquisition (In India or Abroad)To meet out the expenses Marketing and AdvertisementTo meet out the capital expendituresTo meet out the expenditure on Investment in TechnologyTo meet out the General Corporate Purposes
  • andTo meet out the Issue Expenses.

Highlights

  • Offers a wide range of over 50 SKUs, categorized into niche therapeutic areas and lifestyle-based solutions, catering to specific health issues.
  • Ensures product availability across metropolitan areas, Tier 1, Tier 2, and Tier 3 cities through an extensive delivery network and reliable partners.
  • Backed by a dedicated research and development team comprising BAMS doctors, specializing in creating effective and targeted formulations.
  • Successfully conducted clinical trials for key products like Liv Muztang, Dr. Piles Free, and Dr. Madhu Amrit, with results documented in reputed journals like the World Journal of Pharmaceutical Research.
  • Demonstrates consistent revenue growth, with revenue from operations increasing significantly from Rs 51.92 crore in FY22 to Rs 127.91 crore in FY24, alongside a notable rise in profit after tax (PAT).

Challenges

  • A significant portion of the company’s revenue is derived from five states (Tamil Nadu, Uttar Pradesh, Karnataka, Maharashtra, and Andhra Pradesh). Adverse developments in these regions could significantly impact the company’s revenue and overall performance.
  • Product formulations are registered under the names of the contract manufacturers rather than the company itself, which could limit the company's control and ownership over its intellectual property.
  • The company operates in a segment with low entry barriers, making it vulnerable to intense competition and pricing pressures.
  • The company depends heavily on individual promoters and the management team. Losing key personnel or failing to retain and attract qualified staff could disrupt operations and affect financial performance.
  • The promoters are involved in ongoing legal proceedings, and any adverse judgments could harm the company's reputation and business prospects. Additionally, outstanding borrowings (secured and unsecured) pose a risk if the company faces challenges in repayment or servicing of these loans.

Financials

YearsTotal AssetsShare CapitalProfit After TaxConsolidated Net ProfitAdjusted EPS
20221,20,199.237,000.0013,868.8113,868.811.2383
20231,42,817.107,000.0063,054.9663,054.965.6299
20242,12,354.4428,000.0013,868.8113,868.811.2383
Enrich money logo